Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "Lupin"

292 News Found

Lupin receives warning letter from US FDA
Drug Approval | September 30, 2022

Lupin receives warning letter from US FDA

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility


Lupin launches Sildenafil for Oral Suspension in US
Drug Approval | September 30, 2022

Lupin launches Sildenafil for Oral Suspension in US

Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US


Lupin receives approval from US FDA for Diclofenac Sodium Topical Solution USP
Drug Approval | September 23, 2022

Lupin receives approval from US FDA for Diclofenac Sodium Topical Solution USP

Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US


Lupin receives Health Canada approval for Rymti
Drug Approval | September 14, 2022

Lupin receives Health Canada approval for Rymti

Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis


Lupin Launches Generic Suprep Bowel Prep Kit in US
Drug Approval | September 10, 2022

Lupin Launches Generic Suprep Bowel Prep Kit in US

Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (RLD Suprep Bowel Prep Kit) had estimated annual sales of US $202 mn in the US


Lupin and DKSH sign licensing and supply agreement to market five biosimilar candidates in the Philippines
News | September 07, 2022

Lupin and DKSH sign licensing and supply agreement to market five biosimilar candidates in the Philippines

Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.


Lupin receives tentative approval from USFDA for Dasatinib Tablets
Drug Approval | August 29, 2022

Lupin receives tentative approval from USFDA for Dasatinib Tablets

Dasatinib Tablets (RLD Sprycel) had estimated annual sales of USD 1569 million in the U.S. (IQVIA MAT June 2022).


Lupin receives UK MHRA Approval of Lutio for treatment of COPD
Drug Approval | August 27, 2022

Lupin receives UK MHRA Approval of Lutio for treatment of COPD

Lutio has the potential to offer significant cost savings when available to UK patients.


Lupin launches Desvenlafaxine extended-release tablets in the US
News | August 27, 2022

Lupin launches Desvenlafaxine extended-release tablets in the US

Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V.